The Effect of Atorvastatin on Lipid Profile and Inflammatory Marker in patient with Diabetes Dyslipidemia-Reference-Cited by-同舟云学术

The Effect of Atorvastatin on Lipid Profile and Inflammatory Marker in patient with Diabetes Dyslipidemia

Published:2022-09-28 Issue: Volume: Page:4105-4110
ISSN:0974-360X
Container-title:Research Journal of Pharmacy and Technology
language:en
Short-container-title:RJPT

Author:

Bellatasie Rezlie¹,Suharjono Suharjono²,Samsulhadi Wiwid³,Ayumuyas Nur Palestin⁴

Affiliation:

1. Master of Clinical Pharmacy Program, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.

2. Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.

3. Department of Internal Medicine, Surabaya Hajj General Hospital, Surabaya, Indonesia.

4. Department of Hospital Pharmacy, Surabaya Hajj General Hospital, Surabaya, Indonesia.

Abstract

Inflammation is the underlying cause of several comorbid diseases, including macrovascular complications that cause the highest mortality in diabetes patients. One of the pro-inflammatory cytokines used to assess inflammatory conditions in diabetes and its complications is IL-6. This study intends to analyze the effect of atorvastatin administration on lipid profile and inflammatory markers after 30 days and the correlation between lipid profile and IL-6. An observational prospective cohort study was conducted from November 2017 to January 2018 and approved by the ethical committee of General Hajj Hospital, Surabaya. Nineteen patients who met the inclusion criteria and signed the informed consent enrolled in this study. The measurement of lipid profile and IL-6 level were done twice, before and after 30 days of atorvastatin therapy. After atorvastatin administration, there was a 40.55% decrease in LDL level, a 15.34% decrease in TG level, a 30.70% decrease in total cholesterol level, which was statistically significant (p<0.05), and a 6.06% increase in HDL level. There was a 5.76% decrease in the IL-6 level (p>0.05). In conclusion, atorvastatin administration can improve lipid profile in diabetes patients with dyslipidemia. There was a decrease in IL-6 but not statistically different. From statistical analysis, there is no correlation found between lipid profile and IL-6

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference52 articles.

1. Powers AC. Diabetes Mellitus: Diagnosis, Classification, and Pathophysiology. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw Hill Education; 2015.

2. Dipiro JT, Talbert GC., Yee GR., Matzke BG., Wells LMP. Pharmacotherapy: A Pathophysiology Approach, 10th Edition. In: DiPiro JT, Talbert RI, Yee GC, Matzke GR, Wells BG, Posey IM, editors. Mc-Graw Hill Medical. 10th ed. The McGraw-Hill Companies; 2017. p. 6007–48.

3. International Diabetes Federation. Diabetes Atlas [Internet]. 7th ed. Cavan, David; Fernandez, Joao da Rocha; Makaroff, Lydia; Ogurtsova, Katherine; Webber S, editor. Vol. 102, Diabetes Research and Clinical Practice. Brussel; 2015. Available from: www.diabetesatlas.org

4. American Diabetes Association. Standards of medical care in diabetes-2017. Cefalu WT, editor. Vol. 40, Diabetes Care. 2017. 1–142 p.

5. de Souza Bastos A, Graves DT, de Melo Loureiro AP, Júnior CR, Corbi SCT, Frizzera F, et al. Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients. J Dia Comp. 2016;30(8):1593–9.